Manhattan Scientifics Reaches the Fork (Falk) in the Road
Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market
AstraZeneca Starts New Study for Asthma Drug Tralokinumab
Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin
Week ending April 27: Quarterly earnings continue to boost market's spirits.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
Health-care Sector Although the median health-care stock is slightly overvalued in our opinion, we're very excited by the prospects of the health-care sector. Demographics--especially older, wealthier populations--give many of the firms we cover a strong outlook in 2007 and beyond. We're excited ...
Three ways to separate long-term winners from stocks that fizzle.